Drug Trial Radar · NCT07804797
Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
71
Actual
Start
Mar 2, 2026
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Shanghai Minwei Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study adopted a randomized, open-label design, aiming to preliminarily explore the weight-loss maintenance effect of MWN109 tablets when administered continuously for 24 weeks in non-diabetic overweight or obese participants. Participants who met the inclusion criteria were randomly assigned (1:1) to either the QD or QW administration group of MWN109 tablets, with the dose grouping in the MWN109-II-WL study serving as a random stratification factor. This study included a maximum screening period of 2 weeks, a 24-week treatment observation period, and a 2-week safety follow-up period, totaling 28 weeks. The primary endpoint was the percentage change in weight from baseline after 24 weeks of administration. The secondary endpoints included the change in weight from baseline after 24 weeks of administration, as well as the change in waist circumference from baseline.
Conditions
- Overweight , Obesity
Interventions
MWN109 1Drug
Administered orally, QD, 24 weeks
MWN109 2Drug
Administered orally, QW, 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weight compared to baseline after 24 weeks of drug administrationTime frame: Baseline, Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.